Kawasaki Disease

Introduction And Epidemiology

• Acute self-limited systemic vasculitis.
• Primarily affects infants and children under 5 years of age.
• Represents leading cause of acquired pediatric heart disease in developed nations.
• Carries 20-25% risk of coronary artery abnormalities if left untreated.
• Treatment with intravenous immunoglobulin reduces coronary risk to <5%.
• Demonstrates highest incidence in northeast Asian countries including Japan, South Korea, and Taiwan.
• Exhibits male predominance.

Etiology And Pathogenesis

Etiological Factors

• Exact pathogenesis remains completely unknown.
• Presumed infectious trigger in genetically susceptible hosts.
• Infrequent occurrence in infants <3 months implies protective maternal antibodies.
• Rare in adults implies prior exposure yielding immunity.
• Bacterial superantigen toxin theory proposed due to similarities with toxic shock syndrome.
• Demonstrates selective expansion of Vbeta2 and Vbeta8.1 T cells.

Genetic Susceptibility

• Higher susceptibility documented in Asian and Pacific Islander descent.
• Concordance rate among identical twins approaches 13%.
• Linkage studies identify significant associations with polymorphisms in ITPKC, CASP3, BLK, and FCGR2A genes.
• Specific human leukocyte antigen region alleles influence disease risk.

Vascular Pathology

• Panvasculitis predominantly affects medium-sized muscular arteries.
• Primarily targets coronary arteries, but may involve axillary, subclavian, and iliac arteries.
• Arteriopathy progresses through three distinct histological phases.
  • Phase 1 involves neutrophilic necrotizing arteritis occurring in first 2 weeks. Moves from endothelium through coronary wall. Yields saccular aneurysms.
  • Phase 2 involves subacute/chronic vasculitis lasting weeks to years. Driven by lymphocytes, plasma cells, and eosinophils. Yields fusiform aneurysms.
  • Phase 3 involves smooth muscle myofibroblast proliferation. Results in progressive luminal stenosis and occlusive thrombosis.

Clinical Manifestations

Disease Phases

• Acute febrile phase lasts 1-2 weeks. Characterized by unremitting fever and principal acute signs.
• Subacute phase lasts up to 3 weeks. Characterized by periungual desquamation, marked thrombocytosis, and highest risk of sudden death from aneurysms.
• Convalescent phase begins when clinical signs resolve. Continues until erythrocyte sedimentation rate normalizes at 6-8 weeks.

Classic Diagnostic Criteria

• Diagnosis remains purely clinical. Lacks pathognomonic diagnostic test.
• Standard diagnosis requires fever lasting >= 5 days and 4 out of 5 principal clinical features.
• Experienced clinicians may establish diagnosis after 3 or 4 days of fever.

Clinical Feature	Description
Ocular	Bilateral nonexudative bulbar conjunctival injection. Characteristically exhibits limbal sparing.
Mucocutaneous	Erythema of oral and pharyngeal mucosa. Strawberry tongue. Red, cracked, dry lips.
Extremity Changes	Acute phase shows erythema of palms/soles and indurative edema of hands/feet. Subacute phase shows periungual desquamation.
Polymorphous Rash	Maculopapular, urticarial, erythema multiforme-like, or scarlatiniform. Never bullous or vesicular.
Lymphadenopathy	Cervical lymphadenopathy. Usually unilateral. Measures >1.5 centimeters. Non-suppurative.

Non-Cardiac Manifestations

• Musculoskeletal: Arthritis or arthralgia involving small or large joints.
• Gastrointestinal: Unexplained vomiting, diarrhea, severe abdominal pain. Hydrops of gallbladder presents as upper abdominal mass. Mild hepatitis and transaminitis occur.
• Neurological: Extreme irritability prominent in infants. Aseptic meningitis yields cerebrospinal fluid pleocytosis. Transient sensorineural hearing loss. Rare facial nerve palsy.
• Renal/Genitourinary: Sterile pyuria, urethritis, meatitis. Acute renal failure represents rare complication.
• Dermatological: Perianal erythema and desquamation. Reactivation erythema and induration at bacillus Calmette-Guerin inoculation site.

Algorithmic Approach

graph TD
     Classic KD Path
    ClinicalCheck -- Yes --> ClassicKD[Classic Kawasaki Disease Diagnosis]
    ClassicKD --> InitialTx
    
     Initial Management
    InitialTx[Initial Therapy within 10 days:<br/>IVIG 2 g/kg + Low-dose Aspirin 3-5 mg/kg/day] --> HighRiskCheck{High Risk Profile? <br/>Z score >= 2.5, age < 6 months, high Kobayashi}
    
    HighRiskCheck -- Yes --> IntensifiedTx[Intensification Therapy:<br/>Add Corticosteroids, Infliximab, or Statins]
    HighRiskCheck -- No --> MonitorResponse[Monitor Clinical Response]
    IntensifiedTx --> MonitorResponse
    
     Long-term Follow-up & Risk Stratification
    FollowUp[Echocardiography Risk Stratification <br/> Baseline, 1-2 weeks, 6-8 weeks] --> ZScores
    ZScores --> Z1[Level 1 & 2: Z score < 2.5 <br/> Discharge at 12 months if normal]
    ZScores --> Z3[Level 3: 2.5 <= Z score < 5 <br/> Annual Echocardiogram]
    ZScores --> Z4[Level 4: 5 <= Z score < 10 <br/> Annual Echo + Stress Imaging, Aspirin +/- Clopidogrel]
    ZScores --> Z5[Level 5: Z score >= 10 <br/> Echo q6mo + Advanced Imaging, Dual Antiplatelet + Anticoagulation]

Incomplete And Atypical Kawasaki Disease

• Manifests prolonged unexplained fever with fewer than 4 principal clinical features.
• Most common in infants <6 months of age.
• Carries highest risk for developing coronary artery abnormalities due to delayed diagnosis.
• Demands high index of suspicion and evaluation via specific laboratory and echocardiographic algorithms.

Laboratory Criteria For Incomplete KD

• Considered when C-reactive protein >= 3.0 mg/dL or erythrocyte sedimentation rate >= 40 mm/hr.
• Requires >= 3 of the following 6 supplemental criteria:
  • Anemia for age.
  • Platelet count >= 450,000/mm3 after 7th day of fever.
  • Serum albumin ⇐ 3.0 g/dL.
  • Elevated alanine aminotransferase.
  • White blood cell count >= 15,000/mm3.
  • Urine white blood cells >= 10/hpf.

Echocardiographic Criteria For Incomplete KD

• Positive echocardiogram establishes diagnosis if ANY of 3 conditions met:
  • Z score of left anterior descending or right coronary artery >= 2.5.
  • Coronary artery aneurysm directly observed.
  • Presence of >= 3 suggestive features: decreased left ventricular function, mitral regurgitation, pericardial effusion, perivascular brightness, lack of vessel tapering, or Z scores in LAD/RCA between 2 and 2.5.

Kawasaki Disease Shock Syndrome

• Constitutes rare, severe illness manifestation.
• Presents with vasodilatory cardiogenic shock, severe hypotension, and poor systemic perfusion.
• Characterized by markedly elevated C-reactive protein, severe hypoalbuminemia, and profound thrombocytopenia.
• Carries significantly increased risk for intravenous immunoglobulin resistance and giant coronary artery aneurysms.
• Demands immediate intensification of anti-inflammatory therapy and inotropic support.

Investigations And Biomarkers

• Complete blood count reveals leukocytosis with neutrophilia and immature forms.
• Normocytic normochromic anemia frequently present.
• Thrombocytosis occurs typically in second week, occasionally exceeding 1,000,000/mm3.
• Acute phase reactants (erythrocyte sedimentation rate, C-reactive protein) universally elevated during acute phase.
• Elevated N-terminal pro-B-type natriuretic peptide (>500 pg/mL) assists in ambiguous diagnostic cases.
• Neck ultrasonography for lymphadenopathy classically reveals multiple enlarged nodes. Nodes are uniformly hypoechoic with absent necrosis and well-circumscribed margins (cluster of grapes appearance).

Cardiovascular Imaging And Risk Stratification

• Echocardiography serves as primary, noninvasive imaging modality.
• Mandates highest-frequency transducer and accurate body surface area calculation.
• Requires baseline imaging at diagnosis, repeat at 1-2 weeks, and final acute assessment at 6-8 weeks.
• Quantitative Z scores (dimension adjusted for body surface area) of RCA or LAD dictate long-term management and risk.

Z Score Classification	Definition And Morphology	Surveillance Protocol
Level 1	Z score < 2. No involvement. Normal architecture.	Discharge from cardiology if normal at 12 months.
Level 2	2 ⇐ Z score < 2.5. Dilation strictly resolving within 1 year.	Discharge from cardiology if normal at 12 months.
Level 3	2.5 ⇐ Z score < 5. Persistent small aneurysm.	Annual echocardiogram. Consider stress imaging every 2 years.
Level 4	5 ⇐ Z score < 10. Persistent medium aneurysm.	Annual echocardiogram and stress imaging.
Level 5	Z score >= 10 OR absolute >= 8 mm. Large or giant aneurysm.	Echocardiogram every 6 months. Annual stress imaging and advanced imaging (CT/MRI).

Acute Medical Management

Standard Initial Therapy

• Goal involves rapid reduction of systemic inflammation to prevent coronary artery damage.
• Therapy mandates initiation within 10 days of fever onset, but indicated later if systemic inflammation persists.

Medication	Dosage And Administration	Clinical Considerations
Intravenous Immunoglobulin	2 g/kg infused as single continuous dose over 8-12 hours.	Suppresses cytokine production and inhibits complement. Defers live virus vaccines (measles, varicella) for 11 months post-infusion.
Aspirin (Acute Phase)	Historically 30-50 mg/kg/day divided every 6 hours till the patient is afebrile for 6 hours. Recent 2024 AHA guidelines advocate low dose 3-5 mg/kg/day from onset.	Reduces risk of gastrointestinal bleeding and Reye syndrome with lower dose.
Aspirin (Convalescent)	3-5 mg/kg/day once daily.	Maintained for minimum 6-8 weeks for antiplatelet activity in Level 1 and 2, or continued till Z Score normalizes in Level 3, 4 and 5

Intensification Therapy For High-Risk Patients

• Strongly indicated for baseline RCA/LAD Z score >= 2.5, infants <6 months, or high Kobayashi risk score¹.
  • Corticosteroids: Intravenous methylprednisolone 2 mg/kg/day divided every 12 hours. Tapered slowly over 2-4 weeks.
  • Infliximab: Monoclonal tumor necrosis factor-alpha antibody. Dose updated to 10 mg/kg intravenously given over 2 hours.
  • Statins (Atorvastatin): Administered in older children to improve endothelial homeostasis and reduce oxidative stress.

Management Of Intravenous Immunoglobulin Resistance

• Defined as persistent or recrudescent fever 36 hours post-initial IVIG completion.
• Occurs in 10-15% of patients. Carries profoundly increased risk for giant coronary aneurysms.
• Second IVIG Infusion: 2 g/kg administered intravenously.
• Corticosteroid Pulse: Intravenous methylprednisolone 30 mg/kg/day for 1-3 consecutive days.
• Biological Agents: Infliximab (10 mg/kg) or Anakinra (Interleukin-1 receptor antagonist).
• Refractory alternatives include Cyclosporine (inhibits calcineurin pathway), Cyclophosphamide, or Plasma Exchange.

Antithrombotic And Anticoagulation Therapy

• Dual approach required for large aneurysms harboring severe risk of luminal thrombosis.
• Small/Medium Aneurysms (Z score < 10): Low-dose aspirin monotherapy. Consider adding Clopidogrel (1 mg/kg/day) for Z score 5-10.
• Giant Aneurysms (Z score >= 10): Mandates dual antiplatelet therapy plus systemic anticoagulation.
• Systemic anticoagulants include Warfarin (target INR 2-3), Low Molecular Weight Heparin, or Direct Oral Anticoagulants (Apixaban, Edoxaban).

Complications And Long-Term Prognosis

Acute Complications

• Macrophage Activation Syndrome: Potentially fatal complication secondary to cytokine storm. Features continuous fever, hepatosplenomegaly, hyperferritinemia (>684 ng/mL), hypofibrinogenemia. Treat with pulse methylprednisolone and Cyclosporine.
• Acute Myocardial Infarction: Risk peaks dramatically during first 2-3 months. Mandates immediate percutaneous coronary intervention or medical thrombolysis (tissue-type plasminogen activator).

Long-Term Outcomes

• Complete regression to normal internal lumen diameter occurs in 50% of small to medium aneurysms over 1-2 years.
• Regressed aneurysms maintain myointimal thickening and abnormal vascular reactivity.
• Giant aneurysms rarely regress and carry indefinite lifetime risk of ischemia, stenosis, and thrombosis.
• Advanced surveillance utilizing Computed Tomography Angiography or Magnetic Resonance Angiography required annually for large/giant aneurysms.
• Surgical revascularization (coronary artery bypass grafting utilizing arterial grafts) indicated for severe reversible ischemia and complex stenosis.
• Structured health care transition to adult cardiology remains paramount for lifelong surveillance and cardiovascular risk factor management.

Footnotes

1. Kobayashi risk score. High risk of IVIG resistance indicated by a total score of ≥ 4.

   • Sodium ≤ 133 mmol/L (2 points).
   • Days of illness ≤ 4 at initial treatment (2 points).
   • Aspartate aminotransferase ≥ 100 IU/L (2 points).
   • Neutrophils ≥ 80% (2 points).
   • Platelet count ≤ 300,000/μL (1 point).
   • C-reactive protein ≥ 10 mg/dL (1 point).
   • Age ≤ 12 months (1 point).
   ↩